VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
INTERACTIONS
PARTICIPANTS
VALIDATIONS
* Login to view program details and full enterprise executive list.
DATE
JULY 2020
TABLES
18
PAGES
73
EDITION
18
PRICE
USD $5450
Focus On Anti-Obesity Drugs, One of the Largest Segments in the Anti-Obesity Drugs Market.
Will this Market be a Huge Opportunity by 2025?
COVID-19 IMPACT SURVEY
GLOBAL EXECUTIVE SURVEY
Impact of Pandemic & Economic Slowdown
Monitor Market Dynamics!
Early March 2020, we reached out to senior enterprise executives who are driving strategy, business development, marketing, sales, product management, technology and operations at competitive firms worldwide. Our ongoing survey is focused on how this will this affect their business ecosystems. We invite you to participate in our survey and add to collective perspectives. Market movements are tracked for 2020, 2021 and broadly for the period of 2022 through 2025. Critical changes are monitored dynamically for the rest of this year. Updated analytics will reflect new and evolving market realities. Our first update scheduled for May 2020 and another in the Fall. Clients receive complimentary updates during 2020. If your company is a recent client for this project, we may have already reached out to your colleagues to participate in our program. If you're an active player in the space but hasn't yet subscribed to our project, we invite you to participate and share your perspectives. Please sign-up here.
INSIDER ACCESS PRIVILEGES
KEY DIFFERENTIATORS
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlassâ„¢ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Obesity and Overweight Statistics |
| Recent Market Activity |
| Obesity - A Prelude |
| Anti-Obesity Drugs: A Market Characterized by High Unmet Needs |
| Currently Available Anti-Obesity Medications |
| Select Currently Available Short-term and Long-term Anti-Obesity Medication |
| Select Off-Label Drugs for Obesity |
| Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth |
| Semaglutide: Highest Potential in the AOM Pipeline |
| Setbacks of Past Drugs |
| Positive Road Ahead for Belviq |
| Relaunch of Xenical |
| Relaunch of Contrave® |
| Reluctance among Patients, Physicians, and Payers Hurts Market Prospects |
| New Drug Development - High on the Agenda, Despite the Market Restraints |
| Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018 |
| Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018 |
| Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018 |
| Diabetes Drug Companies Attempt to Foray into the Anti-Obesity Drugs Space |
| Competitive Landscape |
| Novo Nordisk - The Leading Player in the Market |
| The United States - The Largest Obesity and Anti-Obesity Market |
| Europe - A Market with Vast Potential |
| Obesity Creeps Up in Developing Countries |
| Global Competitor Market Shares |
| Anti-Obesity Drugs Competitor Market Share Scenario Worldwide (in %): 2020 & 2029 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| F. Hoffmann-La Roche Ltd. (Switzerland) |
| GlaxoSmithKline Plc. (UK) |
| Eisai Co., Ltd. (Japan) |
| Novo Nordisk A/S (Denmark) |
| Rhythm Pharmaceuticals (USA) |
| VIVUS, Inc. (USA) |
| 3. MARKET TRENDS & DRIVERS |
| Alarming Rise in Global Obesity Levels - The Major Growth Factor |
| Classification of BMI |
| Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion |
| Growing Middle Class Population to Drive the Market Growth |
| Childhood Obesity - A Market with Unmet Needs |
| Commercial Weight-Loss Companies Foray into the Market |
| Online Drug Stores Boost Sales |
| Barriers to Development of Effective Drugs |
| Regulatory Additions - A Barrier to Entry? |
| High Drug Development Costs - A Major Setback |
| Weight Loss Alternatives - A Market Dampener |
| 4. GLOBAL MARKET PERSPECTIVE |
| Anti-Obesity Drugs Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Anti-Obesity Drugs Market Share Shift across Key Geographies Worldwide: 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| United States |
| Market Facts & Figures |
| United States Anti-Obesity Drugs Market Estimates and Projections in US$ Million: 2018 to 2025 |
| Canada |
| Canadian Anti-Obesity Drugs Market Estimates and Forecasts in US$ Million: 2018 to 2025 |
| Japan |
| Japanese Market for Anti-Obesity Drugs: Annual Sales Estimates and Projections in US$ Million for the Period 2018-2025 |
| China |
| Chinese Anti-Obesity Drugs Market Growth Prospects in US$ Million for the Period 2018-2025 |
| Europe |
| Market Facts & Figures |
| European Anti-Obesity Drugs Market Demand Scenario in US$ Million by Region/Country: 2018-2025 |
| European Anti-Obesity Drugs Market Share Shift by Region/Country: 2019 VS 2025 |
| France |
| Anti-Obesity Drugs Market in France: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Germany |
| Anti-Obesity Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million for the Period 2018-2025 |
| Italy |
| Italian Anti-Obesity Drugs Market Growth Prospects in US$ Million for the Period 2018-2025 |
| United Kingdom |
| United Kingdom Market for Anti-Obesity Drugs: Annual Sales Estimates and Projections in US$ Million for the Period 2018-2025 |
| Rest of Europe |
| Rest of Europe Anti-Obesity Drugs Market Estimates and Forecasts in US$ Million: 2018-2025 |
| Asia-Pacific |
| Anti-Obesity Drugs Market in Asia-Pacific: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Rest of World |
| Rest of World Anti-Obesity Drugs Market Estimates and Forecasts in US$ Million: 2018 to 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 31 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com